DIRS.INFO The most relevant business & tech news

☆ Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
▼ + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The biotech company booked first-quarter sales of $167 million, with revenue from its Covid shot dropping roughly 90% from the same period a year ago. The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from its RSV vaccine. For the first quarter, Mock said the company is "more encouraged by what we're seeing from a productivity perspective" than the higher sales of its Covid vaccine. Cost of sales was $96 million for the fourth quarter, down 88% from the same period a year ago.

Persons: we've, Stéphane Bancel, Jamey Mock, Mock, OpenAI Organizations: Moderna, LSEG, CNBC, Research, Mock, Merck Locations: Moderna, U.S, America

☆ Mental-health professionals explore AI-powered digital therapeutics to treat patients and improve care
▼ + stars: | 2024-04-29 | by ( Christine Macintyre | ) www.businessinsider.com time to read: +8 min

The fusion of human ingenuity and machine intelligence is offering an innovative approach to personalized mental-health care. They can also use AI to assess the quality of their services and find ways to improve as providers of mental-health care. As technology becomes more involved in mental-health care, ensuring data security, confidentiality, and equitable access to services must be top priorities. How an AI platform is helping mental-health-care providers improve their servicesThe AI platform Lyssn is another tech-driven tool for mental-health services. Lyssn aims to hold providers accountable for improved care, especially because "the quality of mental-health care is highly variable," Imel said.

Persons: —, Christopher Romig, Stella, Shaheen Lakhan, Daniel Rimm, Haig Goenjian, Zac Imel, Michael Tanana, Imel, Darin Carver, Carver, It's Organizations: Service, Therapeutics, Click Therapeutics, Food and Drug Administration, Weber Human Services Locations: Tanana

☆ A longevity researcher is facing backlash for claiming to 'reverse aging.' Scientists say there's no consensus on what it means.
▼ + stars: | 2024-04-28 | by ( Lakshmi Varanasi | ) www.businessinsider.com time to read: +4 min

Read previewHarvard researcher Dr. David Sinclair has found himself at the center of controversy within the longevity community. He's also earned his share of critics who say his research isn't always backed up by sufficient evidence. Animal Biosciences reissued a press release walking back the "reverse aging" claim. But scientists in the field say the issue is even more fundamental: There's no way to reverse aging, much less measure it. That means debates about the semantics of aging will only become more relevant to our daily lives.

Persons: —, David Sinclair, Sinclair, He's, Dr, Nir Barzilai, Matt Kaeberlein —, Matt Kaeberlein, Barzilai, it's, it'll, Andrea Maier, Jeff Bezos, Peter Thiel Organizations: Service, Business, Street Journal, Animal Biosciences, Newsweek, The Academy for Health, Academy for Health, Academy, National Institute, Aging, MIT Technology, National University of Singapore, Longevity

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ 'We can save our planet faster': Robotics tech and software offer efficient reforestation solutions
▼ + stars: | 2024-04-23 | by ( Christine Macintyre | ) www.businessinsider.com time to read: +8 min

Companies are using drones and special software to plant trees and overcome reforestation pain points. Robotics making reforestation more efficientThe tech-driven company Mast Reforestation uses drones and biotechnology to help landowners restore forestland after wildfires. Another company using robotics to plant trees is Flash Forest, which employs automated drones to restore burn sites and other damaged forest areas. To combat this issue, Mast Reforestation uses its custom-built software as a seed-inventory and seed-collection logistics platform. The software helped Mast Reforestation collect enough seeds last year to reforest about 2,100 acres on Sheep Creek Ranch in Montana.

Persons: Matthew Aghai, Aghai, Grant Canary, they're, Chris Ireland, Flash, Randy Johns, Jeff Renton, Forest's Organizations: Service, Global Forest Watch, Forest, Ireland, Business, Flash, Boreal, Keewatin Community Development Association, Flash Forest Locations: forestland, Technology, —, Canada, Ireland, Keewatin, Canadian, Saskatchewan, Montana, , Montana

☆ Andreessen Horowitz raises $7.2 billion, a sign that tech startup market may be bouncing back
▼ + stars: | 2024-04-16 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +3 min

Andreessen Horowitz said Tuesday that it raised $7.2 billion across five different funds, a sign of optimism in the tech startup world, which has seen a dearth of significant exits over the past two years. Deal volume for U.S. venture investments in the first quarter sank to its lowest level since 2017, according to data published earlier this month by PitchBook. The firm raised a $4.5 billion crypto fund in 2022, bringing its total amount raised for crypto and blockchain investments to $7.6 billion. Andreessen Horowitz remains on track to raise more money for its crypto fund and a separate biotechnology fund, a person familiar with the matter told Bloomberg. Andreessen Horowitz wrote a $350 million check to the company, which was just getting started and has yet to make inroads in the residential real estate market.

Persons: Andreessen Horowitz, Ben Horowitz, Marc Andreessen, Horowitz, PitchBook, bitcoin, Adam Neumann Organizations: Bloomberg, PitchBook, Astera Labs, CNBC Locations: Silicon Valley, U.S

☆ Biotech stocks are ready to break out. They just need one more thing
▼ + stars: | 2024-04-10 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.

Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey

☆ Record levels of funding propel Denver-Boulder to the top of the life sciences market
▼ + stars: | 2024-04-08 | by ( Chris Dilella | ) www.cnbc.com time to read: +7 min

The Denver-Boulder region is rapidly emerging as a major hub for the life sciences industry, attracting companies that develop cutting-edge medical treatments and technologies. Life sciences research aims to understand living things, from cells to our planet, to improve health, food and the environment. Founded in 2003, the Bioscience Association supports the growth of life sciences, with a focus on access to capital, education, networking and more. A recent CBRE report found Denver-Boulder to be the top U.S. life sciences real estate market, fueled by record investment from venture capitalists and the National Institutes of Health. Entrepreneurial successThe recent surge in venture capital flowing into Denver-Boulder builds on the area's proven track record of success over the past several decades.

Persons: Tim Schoen, BioMed, Schoen, Elyse Blazevich, Kevin Koch, Koch, Edgewise, We've, Dan LaBarbera, LaBarbera, Dr Organizations: BioMed, CNBC, Blackstone, Flatiron, Enveda Biosciences, Denver, Boulder, Colorado Bioscience Association, Bioscience Association, National Institutes of Health, U.S, Pfizer, Therapeutics, University of Colorado, Edgewise Therapeutics, Research, University of Colorado's Anschutz Medical, Center, Drug, Center for Drug, for Drug, Anschutz Medical Locations: CNBC's, Denver, Boulder, Diego, Boulder , Colorado, San Diego, San Francisco, Seattle, Boston, Cambridge, Massachusetts, Aurora, Rocky, Colorado, Boulder ., Denver's

☆ 10 U.S. states where everyday Americans earn the most money—No. 1 isn't New York or California
▼ + stars: | 2024-04-04 | by ( Kamaron Mcnair | In Kamaronmcnair | ) www.cnbc.com time to read: +1 min

If you had to guess where America's highest earners live, you might imagine the booming metropolis of New York City or the tech-heavy cities that make up Silicon Valley. Workers in the District of Columbia have a higher annual median wage at $84,450, but Massachusetts is the highest-earning state. A number of reasons help workers in Massachusetts earn higher salaries. Top colleges like Harvard University and Massachusetts Institute of Technology, which historically churn out high earners, may also drive Massachusetts' median wages up. Check out the map below to see the median wage in every U.S. state.

Organizations: Bureau of Labor Statistics . Workers, District of Columbia, Harvard University and Massachusetts Institute of Technology Locations: New York City, Massachusetts, District

☆ Monthly Meeting Q&A with Jim Cramer: Everything from energy to Costco to embracing sell-offs
▼ + stars: | 2024-03-29 | by ( Paulina Likos | ) www.cnbc.com time to read: +10 min

Here are the responses from Jim Cramer and Director of Portfolio Analysis Jeff Marks. (Vincent, New York) Jeff Marks: Due to the elevated power needs data centers require, energy demands will be higher. (Steve, Michigan) Jim Cramer: I don't blame you for switching to CrowdStrike from Palo Alto, but I had Palo Alto CEO Nikesh Arora on last week. Jim Cramer: The numbers are no good here right now. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer, Jeff Marks, Vincent, Nikesh Arora, I'm, Gwen, haven't, Peter Lynch, Charlie Scharf, Wells, Nick, it's, Rich Galanti, they'll, Stanley Black, Decker, Morgan Stanley, there's, Danaher, Sam, We've, Laxman Narasimhan, Jim Cramer's, Jim Organizations: Investing Club, Coterra, Palo Alto Networks, Palo, Palo Alto, PepsiCo, Coca, Nvidia, AMD, Magellan Fund, Club, JPMorgan, Broadcom, VMWare, Apple, Developers, Jim Cramer's Charitable, CNBC Locations: Vincent , New York, Eaton, China, Steve , Michigan, Palo Alto, Palo, Wells Fargo, Jim , Arizona, Costco, Elizabeth , Pennsylvania, Linda , Ohio, iPhones, Steve , Mississippi, United States

☆ Want to invest $10,000? Here are 5 ETFs to buy now and hold, according to the pros
▼ + stars: | 2024-03-27 | by ( Ganesh Rao | ) www.cnbc.com time to read: +5 min

CNBC Pro asked several finance experts for their top ETF picks to buy and hold this year. The MSCI USA Value index, accessible to U.S. and Europe-based investors, has run up 14% this year, outperforming the S & P 500. Invesco Nasdaq Biotech ETF For investors wanting exposure to growth stocks, Rees likes the Invesco Nasdaq Biotech ET F (SBIO-GB) in the biotech space. L & G Clean Water ETF Rees, whose firm manages more than $12.6 billion in assets, also highlighted the L & G Clean Water ETF (GLUG-GB) for investors keen on an environmental play. The fund's $415 million is invested across 53 stocks in the Solactive Clean Water Index.

Persons: Vahan Janjigian, Janjigian, Ursula Marchioni, Marchioni, Ian Rees, Rees, It's Organizations: CNBC Pro, Vanguard, Stock, Greenwich Wealth, BlackRock, Premier Miton Investors, Nasdaq Biotech, Nasdaq, Nasdaq Biotech ETF, U.S, London Stock Exchange, Index, Vanguard FTSE Locations: U.S, Europe, East, Asia, Germany

☆ Stocks making the biggest moves midday: Krispy Kreme, Trump Media, McCormick and more
▼ + stars: | 2024-03-26 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Krispy Kreme — Krispy Kreme popped nearly 30% and headed for its best day on record. Trump Media & Technology Group — Shares of former President Donald Trump's social media company surged 35% after it began trading on the Nasdaq . Trump Media completed its merger with shell company Digital World Acquisition Corp . McCormick — The stock jumped 10% after the spice maker topped earnings and revenue expectations for its fiscal first quarter. Reddit — Reddit popped about 15% as investors continued buying up the social media stock following its Thursday debut on the New York Stock Exchange .

Persons: Kreme, McDonald's, Donald Trump's, McCormick, Morgan Stanley, Alex Harring, Michelle Fox, Jesse Pound, Pia Singh Organizations: Trump Media & Technology, Nasdaq, Trump Media, Revenue, New York Stock Exchange, Viking Therapeutics, Seagate Technology, Micron Technology, Mizuho Securities, UPS —, UPS, JPMorgan Locations: FactSet

☆ Nvidia's AI ambitions in medicine and health care are becoming clear
▼ + stars: | 2024-03-24 | by ( Michelle Castillo | ) www.cnbc.com time to read: +3 min

Last week, Nvidia announced deals with Johnson & Johnson for use of generative AI in surgery, and with GE Healthcare to improve medical imaging. "Health care, whether it's biotechnology, chemicals, or drug discovery is a very powerful area." About 41 percent of biotech CEOs surveyed by EY in late 2023 said they were looking at "concrete" ways generative AI could be used for their companies. "This is very high for my experience, having been 30 years in this industry," Ural said. It also partnered in 2021 with Schrödinger for drug discovery.

Persons: Johnson, Raj Joshi, It's, EY, it's, Colette Kress, Roche's Genentech Organizations: Nvidia, Johnson, GE Healthcare, Companies, NVIDIA, NVIDIA BioNeMo Locations: Arda, Americas, Ural, NVIDIA Clara

☆ Nvidia has a parade of partners, but these two stocks are my favorite beneficiaries
▼ + stars: | 2024-03-24 | by ( Jim Cramer | ) www.cnbc.com time to read: +23 min

That's what Nvidia needed semiconductor design firm Synopsys to do to make this next generation of chips. Right now, Nvidia has had not one, but two different breakthroughs: Accelerated computing at a ridiculously fast speed and generative artificial intelligence. I think Jensen regards Dell as a crucial partner when it comes to installing Nvidia's systems anywhere. Do I think Nvidia would like to do more business with Apple? I think Nvidia would like to do more business with everyone, including alleged opponent Intel .

Persons: Abraham Lincoln, David Herbert Donald, Jensen, It's, Jensen Huang, Lincoln, Leonardo da Vinci, da Vinci, he's, Blackwell, Grace Hooper Superchip, –, Moby Dick –, that's, they've, Adam Selipsky, Jensen laughingly, Claude, Anthropic, Dell, Michael Dell, Jensen's, it's, dink, I'm, Johnson, J, Abbott, Reckitt Benckiser, we've, CrowdStrike, ServiceNow, Bill McDermott, Tesla, Elon Musk, Lora Kolodny, That's, Frank Slootman, Ansys, Synopsys, isn't, Sundar Pichai, Satya Nadella, Larry Ellison, Nvidia's Blackwell, Mark Zuckerberg, Jim, Tim Cook, Cook, Apple, Jim Cramer's, Jim Cramer, Josh Edelson Organizations: Lincoln, GTC, Nvidia, GTC –, CNBC, Amazon, Microsoft, Google, Dell Technologies, Club, Dell, Siemens, Rockwell Automation, Cadence Design Systems, Nvidia's, Johnson, Abbott Laboratories, GE Healthcare, cybersecurity, Palo Alto, Palo, Snowflake, AMD, Autodesk, Cadence, Computer, Oracle, Apple, Justice Department, Intel, Vision, Jim Cramer's Charitable, SAP Center, AFP, Getty Locations: U.S, Silicon Valley, Lincoln, Here's, Palo Alto, Pittsburgh, Switzerland, San Jose , California

☆ Morgan Stanley's guide to investing in AI as use of the technology spreads
▼ + stars: | 2024-03-14 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Morgan Stanley is offering up alternative ways to play artificial intelligence beyond the usual tech "enablers" that have come to dominate investor attention. A report issued Tuesday entitled "15 Ways to Play AI" anticipates a "broadening out of the AI theme over the remainder of 2024 and into 2025" and notable AI adoption in areas such as gaming, education and biotechnology. The study, an outgrowth of Morgan Stanley's technology, media and telecom investment conference last week, highlights "the Tech Diffusion theme from all angles and all geographies." Against this backdrop, here are some of Morgan Stanley's top picks as AI broadens out: Several popular technology stocks made the list alongside AI mainstays such as Nvidia , Microsoft and Alphabet . Morgan Stanley included workplace management software company Asana on two of its AI lists, one of companies that are likely to get a productivity boost from AI, and another that highlighted "Global Adopters" of AI.

Persons: Morgan Stanley, Morgan, Edward Stanley, —, Stanley, Morgan Stanley's, Oracle, Asana, Baker Hughes, Prologis, AbbVie Organizations: Microsoft, Meta, Edge, Companies, Nvidia, Apple, Baidu, Palantir Technologies Locations: London, Europe, ASAN

☆ Montana rancher paid $4,200 to clone a dead sheep and launched a farm of super hybrids worth up to $550,000
▼ + stars: | 2024-03-14 | by ( Jenny Mcgrath | ) www.businessinsider.com time to read: +7 min

A Montana rancher was charged with illegally selling offspring from a cloned sheep across state lines. There's nothing illegal about selling sheep for exorbitant prices — unless those animals are Marco Polo argali sheep, or in Schubarth's case, hybrids of Marco Polo argali sheep. Marco Polo argali sheep are native to central Asia and are considered threatened under the US Endangered Species Act. Shortly thereafter, Schubarth allegedly got his hands on some of those sheep parts and, in 2015, paid a deposit of $4,200 to produce cloned sheep embryos from the dead argali's remains. AdvertisementIn May 2017, a pure argali sheep was born from one of those cloned embryos.

Persons: —, Arthur, Jack, Schubarth, Marco Polo, George Schaller, Joyce Tischler, Lacey, King, Matthew Polak, Dolly, it's, Alison Van Eenennaam, Davis, Van Eenennaam, Gregory Kaebnick, isn't, Rula Rouhana, Reuters It's, Kaebnick, didn't Organizations: Service, Department, Lewis & Clark Law School's Center for Animal Law, European Union, Getty, University of California, and Wildlife Service, The Hastings Center, Reproductive Biotechnology, Reuters Locations: Montana, Asia, Kyrgyzstan, Dubai

☆ Stocks making the biggest moves midday: Tesla, GE HealthCare, Coinbase and more
▼ + stars: | 2024-03-13 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Crypto stocks — Stocks whose performance is tied to the price of bitcoin rose as the cryptocurrency pushed to another record for the third day in a row. Dollar Tree posted adjusted earnings of $2.55 per share on $8.64 billion of revenue for the fourth quarter. Analysts surveyed by LSEG, formerly known as Refinitiv, had penciled in $2.65 per share on $8.67 billion in revenue. GE HealthCare — Shares dropped 3% after the medtech company announced a secondary offering of 13 million shares. Analysts had expected earnings of 2 cents per share on revenue of $1.62 billion, per LSEG.

Persons: Coinbase, MicroStrategy, CleanSpark, Baird, Goldman Sachs, Wells, Raymond James, —, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Michelle Fox Organizations: Marathon, Iris Energy, Texas, Nvidia, Devices, Micron Technology —, Micron, AMD, LSEG, GE, —, GE HealthCare Technologies, General Electric, Royal, Petco, Wellness Locations: Kentucky, Royal Caribbean

☆ Here are Tuesday's biggest analyst calls: Apple, Tesla, Coinbase, Sony, Oracle, FedEx, Nike, Carvana & more
▼ + stars: | 2024-03-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

"We initiate coverage on Regeneron with an Outperform rating and $1,125 price target." Canaccord reiterates MicroStrategy as buy Canaccord raised its price target on the crypto company to $1,810 per share from $975. "We are initiating coverage of The New York Times with a Buy rating and a $52 target price. "DG – Upgrading to Neutral Raising Price Target to $158." "We are initiating coverage of Central Garden & Pet ( CENT) with a BUY rating and $52 price target."

Persons: Bernstein, Morgan Stanley, Tesla, it's, optionality, Canaccord, Goldman Sachs, PDD, Goldman, Jefferies, underperform Jefferies, Raymond James, underperform Raymond James, Argus, Evercore, William Blair, Goldman Sacks Organizations: Citi, New York Times, Nike, JPMorgan, RBC, Bank of America, Apple, Oracle, Central, FedEx, Macquarie, Sony Locations: China

☆ A veteran chartmaster calling for a continued market rally says it's time to diversify away from mega-cap growth by making these 6 investments now
▼ + stars: | 2024-03-10 | by ( James Faris | ) www.businessinsider.com time to read: +5 min

Wall Street was mostly upbeat about equities heading into 2023, though even the most bullish investment firms thought the S&P 500 would finish this year at 5,100 — a level it has exceeded already. Resisting this rally is a fool's errand, according to David Keller, the chief market strategist at StockCharts.com. The long-time chartmaster warned of a near-term pullback as the S&P 500 approached its previous record high but has since abandoned his cautious call. AdvertisementFast-forward to early March, and many of those mega-cap growth names remain hot, especially Nvidia and Meta. "I like that idea, at this point, of diversifying away from mega-cap growth," Keller said.

Persons: —, David Keller, chartmaster, Keller, I'm, they've, StockCharts.com Organizations: Service, Business, Nasdaq, Nvidia, Meta, Microsoft, Apple, Companies, Hilton, Marriott, Restaurant Brands, Burger King ., Biotechnology Locations: Burger

☆ With the Nasdaq at record highs, these are the benchmark's most beloved stocks that are expected to rally
▼ + stars: | 2024-03-01 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Even as the Nasdaq Composite is surging to new highs, investors can still find stocks within the index that have room to run. These stocks have a consensus buy rating from analysts and have an upside of 20% or more from their average price targets. Analysts have a consensus buy rating on both stocks, and think AstraZeneca could rally more than 26%, while Biogen could jump roughly 40%. Bank of America last month reiterated its buy rating on Baker Hughes. Twenty-two of the 27 analysts polled by LSEG rate the stock a buy or strong buy, and the average price target suggests 35% upside from here.

Persons: Biogen, Wells, Baker Hughes, Saurabh Pant Organizations: Nasdaq, CNBC, Stock, AstraZeneca, Warner Bros, Biotechnology, Biogen, Deutsche Bank, Analysts, Moderna, HSBC, Discovery, Bank of America, CCS, " Bank of America

☆ Move over Big Tech, a new market leader could be emerging, according to the charts
▼ + stars: | 2024-02-29 | by ( David Keller | ) www.cnbc.com time to read: +3 min

Biotechnology stocks have recently shown renewed strength, and improving momentum may just push these names toward the top of the leaderboard. Second, this level also represented a 38.2% retracement level based on the 2021 high and 2022 low, which is a widely followed support level based on the Fibonacci methodology. This week, IBB has bounced off that support level, making a new 52-week high as it briefly pushed above the 50% retracement level around $140. The weekly chart reinforces that biotechnology stocks may still be in the early stages of this advance, with lots of daylight between current levels and the 2021 highs. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.

Persons: IBB, David Keller Organizations: Biotechnology, Nasdaq Biotechnology, CMT

☆ Here are the 10 stocks that large-cap money managers are getting most excited about right now, according to UBS
▼ + stars: | 2024-02-29 | by ( James Faris | ) www.businessinsider.com time to read: +2 min

Large-cap fund managers are starting to shy away from several of the biggest companies in the S&P 500, according to a recent report from UBS. By bailing on those three names and top performers like Nvidia (NVDA), money managers are swimming against the tide. That's why large-cap stock-pickers tend to fade the biggest companies, according to UBS. 10 stocks that fund managers loveBy contrast, fund managers' largest relative overweight positions are in sectors like industrials, financials, healthcare, and materials, Palfrey noted. Below are the 10 companies that are seeing the biggest improvements in sentiment from large-cap fund managers, as measured by the net number of funds adding positions to them.

Persons: Patrick Palfrey, Palfrey Organizations: UBS, Microsoft, Apple, Business, Nvidia

☆ 'Boomer nation' is in charge, hedge fund manager shares what sectors to focus on
▼ + stars: | 2024-02-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'Boomer nation' is in charge, hedge fund manager shares what sectors to focus onDavid Neuhauser of Livermore Partners says that we are in a "boomer renaissance" and expects tourism, healthcare and biotechnology stocks to benefit.

Persons: David Neuhauser Organizations: Livermore Partners

☆ This sector offers defensive and growth properties – along with some portfolio income
▼ + stars: | 2024-02-26 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +6 min

The health-care sector of the S & P 500 is up about 8% year to date, marking a sharp comeback from a largely flat 2023. Even as health care is making a comeback this year, investors shouldn't forget its defensive attributes. Back in 2022, when the S & P 500 fell 19.4%, the health-care sector slipped only 3.5% "When markets are challenged, health care can be a good place to be," Lyons added. Some of them speak to the growth aspects of health care and why you can play offense." Merger activity is another driver of growth in health care, as large pharmaceutical companies snap up nimble biotech firms that are at the forefront of developing treatments.

Persons: Dan Lyons, Janus Henderson, shouldn't, Lyons, ImmunoGen, Seamus Fernandez, Sotatercept, Cigna, Cantor Fitzgerald, Sarah James, Fred Imbert Organizations: Big Tech, . Healthcare, Janus, Janus Henderson Investors, U.S . Food, Drug Administration's Center, Drug, Research, FDA, Esai, Pharmaceuticals, CNBC Pro, Merck, Abbott Laboratories, AbbVie, CVS Health Locations: U.S

☆ JPMorgan says buy this immunology stock primed to rally nearly 40%
▼ + stars: | 2024-02-20 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Immunovant could emerge as a key player in the autoimmune space, according to JPMorgan. The bank initiated coverage of the biotech stock at an overweight rating, also setting a price target of $51. That implies that shares of Immunovant could rally more than 37% from their Friday closing price of $37.13. Immunovant stock has slid 9% so far this quarter. IMVT YTD mountain IMVT YTD chart As a key catalyst, the analyst underscored Immunovant's stats as one of the key players using anti-neonatal Fc receptor technology, or anti-FcRn technology, to treat autoimmune diseases.

Persons: Brian Cheng, Graves, Cheng, — CNBC's Michael Bloom Organizations: JPMorgan, IMVT, Telavant, Merck, Prometheus Locations: Immunovant, IMVT, Roche

Search resuls for: "Biotechnology"

25 mentions found